A retrospective study to assess Enzalutamide as a Fourth- or Fifth-Line Treatment Option for patients with Metastatic Castration-Resistant Prostate Cancer.
Phase of Trial: Phase IV
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Enzalutamide (Primary) ; Abiraterone acetate; Cabazitaxel; Docetaxel
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Mar 2017 New trial record